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1Since the first transcatheter aortic valve implantation1 (TAVI) in 2002 and the establishment of the retrograde 
transfemoral approach2 in 2005, the procedure has undergone 
further refinements.3 Lower profile delivery systems,4 multi-
modality imaging for patient screening5 and device deploy-
ment,6 transcatheter heart valve (THV) sizing algorithms,7 and 
modifications of prosthesis design8 and delivery systems have 
reduced the rate of vascular complications4 and paravalvular 
regurgitation7 (PAR) and increased the safety and efficacy 
of TAVI.9,10 Although the procedure was initially restricted 
to inoperable patients,11 it is currently approved for operable 
patients at high surgical risk.12 Recently, a randomized trial13 
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has indicated superiority of TAVI over surgical aortic valve 
replacement for 1-year survival in patients with symptomatic 
severe aortic stenosis and a mean Society of Thoracic Surgeons 
Predicted Risk of Mortality (STS PROM) of 7.3±3.0%, indi-
cating intermediate surgical risk.
In 2014, the newest generation balloon-expandable THV14 
(Sapien 3, S3; Figure 1) received regulatory approval and was 
introduced in Switzerland and subsequently replaced its pre-
decessor the Sapien XT (XT; Figure 2) THV as the default 
balloon-expandable THV for TAVI. The S3 may be delivered 
via a lower profile delivery system and incorporates a sealing 
cuff intended to reduce PAR. Despite positive results during 
the first-in-human S3 experience14 and subsequent small15,16 
series, it is not established whether the new features of the S3 
will translate into improved procedural and clinical outcomes 
compared with the XT. We therefore analyzed and compared 
all patients who underwent transfemoral TAVI with the S3 or 
the XT in the prospective, nationwide Swiss TAVI registry in 
Switzerland (ClinicalTrials.gov NCT01368250).
Methods
The Swiss TAVI registry is—as previously described17—a nation-
al, prospective cohort study of all TAVI procedures performed in 
Switzerland aiming for consecutive patient enrollment and with data 
monitoring as well as end point adjudication by a dedicated clini-
cal events committee according to the recommendations of the Valve 
Academic Research Consortium.18 The Swiss TAVI registry was de-
signed to provide short-term clinical outcomes and long-term clinical 
data of TAVI patients treated with CE-approved devices. The study 
protocol was approved by the local cantonal ethics committee and 
institutional review boards at each participating center, and all pa-
tients provided written informed consent. The Swiss TAVI registry 
is performed under the lead of the Swiss Cardiovascular Center Bern 
at Bern University Hospital in cooperation with the Clinical Trials 
Unit Bern responsible for data management and independent statisti-
cal analysis.
For this analysis, all patients of the Swiss TAVI registry who un-
derwent transfemoral TAVI with either the XT or the S3 THV were 
analyzed (inclusion period: XT, February 2011 to January 2014; S3, 
February 2014 to June 2014). The grade of PAR was assessed by 
transthoracic echocardiography before hospital discharge by highly 
experienced echocardiographers according to Valve Academic 
Research Consortium-2 guidelines.18 Prespecified end points were 
more than mild PAR, vascular complications, major bleeding, new 
permanent pacemaker implantation (PPM), disabling stroke, and 
mortality after 30-day of follow-up.
Statistical Analysis
Continuous data are reported as mean±standard deviation (SD), and 
categorical variables are reported as number of patients (% of pa-
tients). Events are reported as counts of first occurrence per (sub) 
type of event (% of all patients). Event probabilities at 30 days were 
compared for patients treated with the XT versus the S3 bioprosthesis 
using logistic regressions. Reported are crude odds ratios (with 95% 
confidence intervals) with P values from Wald χ2 tests corrected for 
random effects of the hospital identifier using mixed effects logistic 
regressions or exact logistic regression odds ratios with P values from 
exact tests in case of zero events. Reported are adjusted odds ratio 
(95% confidence interval), with the 2 valves compared using mixed 
effects logistic regressions, including (1) adjustment for TAVI proce-
dure date (ie, to account for a potential learning effect of time), (2) 
random effect of hospital identifier, and (3) adjustment for baseline 
characteristics using inverse probability of treatment weights (ie, to 
account for potential disbalances between the 2 valve types concern-
ing the patient population treated). The estimates of adjusted odds 
ratio from 20 data sets after multiple imputation of missing values 
were combined using Rubin’s rule and presented with adjusted P val-
ues (P
adj). Inverse probability of treatment weights for S3 versus XT 
THV was calculated within each of the 20 data sets using the follow-
ing baseline variables: age, sex, body mass index, diabetes mellitus, 
dyslipidemia, hypertension, previous pacemaker, history of myocar-
dial infarction, cardiac surgery, cerebrovascular event, peripheral 
vascular disease, chronic obstructive pulmonary disease, coronary 
artery disease, left ventricular ejection fraction, aortic valve area, 
mean aortic valve gradient, moderate or severe mitral regurgitation, 
New York Heart Association class III or IV, Canadian Cardiovascular 
Society angina class none or I/II or III/IV, logistic EuroSCORE, STS 
PROM score, and valve size. No adjusted analyses were performed 
WHAT IS KNOWN
•	Transcatheter aortic valve implantation (TAVI) with 
the Sapien XT transcatheter heart valve (THV) is a 
valuable alternative to surgical aortic valve replace-
ment in selected patients.
•	However, TAVI is associated with vascular and 
bleeding complications, paravalvular regurgitation, 
and atrioventricular conduction disturbances.
WHAT THE STUDY ADDS
•	 In this preliminary comparison, the use of the new 
generation Sapien 3 THV was associated with a 
lower incidence of vascular complications and less 
paravalvular regurgitation compared with TAVI with 
the Sapien XT THV.
•	The rate of new pacemaker implantation was higher 
after TAVI with the Sapien 3 THV than after TAVI 
with the Sapien XT THV.
Figure 1. Aortic root angiogram after Sapien 3 transcatheter 
heart valve implantation. The Sapien 3 transcatheter heart valve 
comprises a balloon expandable, cobalt chromium frame, a 
trileaflet bovine pericardial tissue valve, and a polyethylene 
terephthalate (PET) skirt. The outer PET cuff was designed to 
improve paravalvular sealing.
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for outcomes with <10 events overall. Two-sided P values <0.05 were 
considered statistically significant. All analyses were performed with 
Stata version 14 (StataCorp, College Station, TX).
Results
Overall, 153 consecutive S3 patients and 445 consecutive XT 
patients were included in this study. The cohort represents con-
secutive all-comers with symptomatic severe aortic stenosis 
undergoing transfemoral TAVI with a balloon-expandable THV 
in Switzerland. Baseline characteristics are shown in Table 1. 
Except for dyslipidemia, which was more prevalent in patients 
receiving the XT THV, there were no significant differences 
in baseline characteristics. Importantly, no significant differ-
ences were found for age (82.2±6.1 versus 82.2±6.8 years, 
P=0.94), STS PROM (7.2±6.5% versus 8.5±7.9%, P=0.07), 
and preprocedural mean aortic valve gradient (47.2±22.0 ver-
sus 43.7±17.3 mm Hg, P=0.06) between S3 and XT patients, 
respectively.
Some procedural characteristics changed during the 
course of the trial (Table 2). Because of the establishment 
of hybrid operating rooms, more S3 patients were treated 
in this setting (S3 32.7% versus XT 22.9%, P=0.02) com-
pared with XT patients who were mostly treated in cardiac 
catheterization laboratories (S3 66.7% versus XT 77.1%, 
P=0.01). Although procedural time did not change, there was 
less contrast dye used in S3 patients (S3 158.0±87.4 versus 
XT 201.2±95.4 mL, P<0.01), and there appeared a trend to 
perform the procedure without the use of general anesthe-
sia in S3 patients (S3 69.9% versus XT 61.3%, P=0.06). 
Postprocedural mean transprosthetic gradient (6.5±3.0 versus 
7.8±6.3 mm Hg, P=0.17) did not differ between S3 and XT 
patients, respectively.
Significant differences in the occurrence of PAR (Figure 3) 
were observed between S3 and XT patients. In more than 
half of S3 patients, no PAR was detected (57.3%), although 
this was observed in only one third of XT patients (31.9%, 
P<0.01). Mild PAR was also less frequent in S3 compared 
with XT patients (S3 41.3% versus XT 62.9%, P<0.01). 
Furthermore, the rate of more than mild PAR was significantly 
lower in S3 compared with XT patients (S3 1.3% versus XT 
5.3%, P=0.04).
At 30-day (Table 3) follow-up, mortality did not dif-
fer between S3 and XT patients (S3 3.3% versus XT 4.5%, 
P=0.52, P
adj=0.27). Major disabling stroke was low in both 
groups (S3 1.3% versus 3.1%, P=0.24, P
adj=0.29). The rate of 
PPM implantation was higher in S3 patients (S3 17.0% versus 
XT 11.0%, P=0.06, P
adj=0.01). Major bleeding occurred twice 
as often in XT patients than in S3 patients (S3 3.9% versus XT 
8.3%, P=0.11, P
adj=0.81) albeit not significantly different, but 
the rate of vascular complications (major and minor) was sig-
nificantly higher in XT patients (S3 5.2% versus XT 16.9%, 
P<0.01, P
adj<0.01).
Discussion
This study sought to investigate differences in procedural and 
clinical outcomes of patients undergoing transfemoral TAVI 
with the S3 versus the XT THV. Analysis of our nationwide, 
prospective Swiss TAVI registry showed that TAVI with the 
S3 significantly reduced PAR and vascular complications in 
comparison to TAVI with the XT.
The success of TAVI depends on the risk of perioperative 
complications, the predictability of the procedure, and device 
durability. Within the last decade, multimodality imaging for 
patient screening, patient selection, and device deployment 
and iterations to the bioprostheses and refinement of delivery 
systems have contributed to the successful global spread of 
TAVI as an alternative to surgical aortic valve replacement. 
Minimizing the rate of periprocedural complications is man-
datory to broaden the indication of TAVI from prohibitive or 
high surgical risk to intermediate13,19 and low surgical risk19 
patients. Considering the S3 as a step into this direction has to 
be based on firm scientific evidence. Important complications 
of TAVI that need to be reduced are stroke, PAR, vascular and 
bleeding complications, and atrioventricular block.
Paravalvular Regurgitation
PAR is frequently observed after TAVI20 and is associated 
with worse survival in patients with moderate to severe PAR.21 
Whether mild PAR is an independent mortality predictor, as 
suggested by a previous study,22 is a matter of controversy. 
Important predictors for PAR include severe leaflet, annulus 
and left ventricular outflow tract calcifications, THV under-
sizing, and THV malpositioning. New THV designs with 
peri-prosthetic sealing cuffs (eg, the S3) may contribute to a 
reduction in PAR. In our study, more than mild PAR was less 
frequently observed after TAVI with the S3 compared with the 
XT. This may be attributed to the external skirt of the S3. How-
ever, improved sizing algorithms and a broader landing zone of 
the elongated S3 stent frame may also have contributed to the 
difference. As more than mild PAR is associated with higher 
mortality,21 this difference may translate into improved TAVI 
Figure 2. Aortic root angiogram after Sapien XT transcatheter 
heart valve implantation. The Sapien XT transcatheter heart valve 
is approved for the treatment of symptomatic severe aortic ste-
nosis in patients at high or prohibitive surgical risk. It comprises 
a balloon-expandable cobalt chromium frame, a trileaflet bovine 
pericardial tissue valve, and a polyethylene terephthalate inner 
skirt.
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outcomes. However, as the rate of more than mild PAR was 
low in our cohort, it did not impact short-term survival.
Stroke
Compared with medical management, TAVI is associated with an 
increased stroke risk.11 Furthermore, in the Placement of Aortic 
Transcatheter Valve (PARTNER) trial, patients undergoing TAVI 
had a higher 30-day rate of any cerebrovascular event compared 
with patients randomized to surgical aortic valve replacement.12 
However, this difference disappeared at 2-year follow-up.22 Sub-
sequent studies with newer generation devices and large registries 
have further calmed the debate about TAVI associated stroke risk.9 
In the French Aortic National CoreValve and Edwards Registry 
(FRANCE II) study,23 stroke rates were 2.3%, and in the United 
Kingdom Transcatheter Aortic Valve Implantation (UK TAVI) 
registry,24 the rate was 4.1%. In our study, the 30-day disabling 
stroke rate with the S3 in an all-comer population was as low as 
1.3%, which was numerically lower than that for the XT. If and 
how the incidence of stroke can be further reduced is a matter of 
debate. Cerebral protection devices25 were designed to capture or 
deflect debris during TAVI, which would have otherwise emboli-
zed to the brain. However, there is currently no evidence that sup-
ports the routine use of these devices.26 The clinical significance 
of a reduction in subclinical lesions on brain scanning post TAVI, 
which has been shown with the Claret device (Claret Embolic 
Protection and TAVI [CLEAN-TAVI] trial, NCT01833052, pre-
sented at Transcatheter Cardiovascular Therapeutics Congress 
2014), was not established. Future clinical trials are needed to 
prove whether these devices effectively reduce the risk of stroke 
during TAVI. In our study population, a cerebral protection device 
was rarely used and not documented in the files.
Vascular Complications
Major vascular complications during TAVI are independent 
predictors of mortality.27 With the first generation balloon-
expandable THV, major vascular complications occurred in 
Table 1. Baseline Characteristics
Sapien 3, N=153 Sapien XT, N=445 P Value
Age, years 82.21±6.05 82.26±6.75 0.94
Female gender, n (%) 72 (47.1%) 249 (55.8%) 0.07
Body mass index, kg/m2 26.90±5.56 26.75±4.95 0.75
Cardiac risk factors
  Diabetes mellitus, n (%) 39 (25.5%) 112 (25.1%) 0.92
  Dyslipidemia, n (%) 65 (42.5%) 236 (52.9%) 0.03
  Hypertension, n (%) 117 (76.5%) 353 (79.1%) 0.49
Past medical history
  Previous pacemaker implantation, n (%) 15 (9.8%) 35 (7.8%) 0.49
  Previous myocardial infarction, n (%) 24 (15.7%) 67 (15.0%) 0.89
  Previous cardiac surgery, n (%) 17 (11.1%) 59 (13.2%) 0.57
  Previous cerebrovascular accident, n (%) 20 (13.1%) 51 (11.4%) 0.56
Clinical features
  Peripheral vascular disease, n (%) 24 (15.7%) 65 (14.6%) 0.79
  Chronic obstructive pulmonary disease, n (%) 22 (14.4%) 52 (11.7%) 0.39
  Coronary artery disease, n (%) 86 (56.2%) 242 (54.3%) 0.71
  Left ventricular ejection fraction, % 56.66±14.67 56.26±13.51 0.78
  Aortic valve area, cm2 0.71±0.23 0.71±0.22 0.88
  Mean transaortic gradient, mm Hg 47.18±22.04 43.74±17.27 0.06
  Mitral regurgitation grade moderate or severe 21 (14.2%) 86 (20.5%) 0.11
  New York Heart Association (NYHA) Class
   NYHA I or II, n (%) 48 (32.9%) 150 (33.7%) 0.92
   NYHA III or IV, n (%) 98 (67.1%) 295 (66.3%) 0.92
  Canadian Cardiovascular Society Angina Class n=152, n=446, 0.15
   No angina, n (%) 125 (82.2%) 333 (74.7%) 0.06
   CCS I or II, n (%) 19 (12.5%) 75 (16.8%) 0.25
   CCS III or IV, n (%) 8 (5.3%) 38 (8.5%) 0.22
Risk assessment
  Log. EuroScore, % 23.71±15.95 21.01±15.99 0.16
  STS score, % 7.15±6.50 8.52±7.98 0.07
Dyslipidemia was more prevalent in the Sapien XT group. All other baseline characteristics did not differ 
significantly between groups. CCS indicates Canadian Cardiovascular Society; and STS, Society of Thoracic 
Surgeons.
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16.2% of patients in the PARTNER IB trial.11 Meanwhile, 
downsizing of access sheath diameters4 allowing fully per-
cutaneous procedures28 has resulted in decreased vascular 
complications. In our study, major and minor vascular com-
plications were significantly lower in S3 compared with XT 
patients. This parallels a study that showed decreased vascular 
complications with lower-profile compared with large-profile 
sheaths.4 On a large scale, the reduction of major vascular 
complications with the S3 delivery system is expected to 
impact prognosis and speed up postprocedural patient mobili-
zation, allowing earlier ambulation and discharge.
Bleeding
Major bleeding and blood transfusions after TAVI are associ-
ated with worse prognosis.29,30 The source of bleeding may be 
procedure-related (eg, access site, ventricular or aortic perfora-
tion) or technically unrelated to TAVI but triggered by periproce-
dural antithrombotic medication (eg, gastrointestinal). The access 
site is the most common source of procedure-related bleeding. 
In this study, major bleeding occurred twice as often in patients 
receiving the XT than in patients treated with the S3 THV; how-
ever, the difference did not reach statistical significance. A lower 
rate of bleeding with the S3 may be attributed to the lower profile 
of the introducer sheath and delivery system. This observation 
parallels a study that compared TAVI outcomes with different 
sheath sizes4 and may translate into improved outcomes.
Permanent Pacemaker Implantation
Atrioventricular conduction disturbances necessitating 
PPM implantation are frequently observed after TAVI11 and 
Table 2. Procedural Characteristics
Sapien 3, N=153 Sapien XT, N=445 P Value
Procedure time, min 71.72±30.54 71.80±27.98 0.98
Amount of contrast, mL 158.04±87.39 201.18±95.37 <0.01
General anesthesia, n (%) 46 (30.1%) 172 (38.7%) 0.06
Lenght of hospital stay, days 9.07±5.72 9.52±5.31 0.38
Type of access 0.82
  Percutaneous, n (%) 133 (86.9%) 390 (87.6%) 0.89
  Surgical, n (%) 20 (13.1%) 55 (12.4%) 0.89
Procedure location
  Catheterization laboratory, n (%) 102 (66.7%) 343 (77.1%) 0.01
  Operating room, n (%) 1 (0.7%) 0 (0.0%) 0.26
  Hybrid room, n (%) 50 (32.7%) 102 (22.9%) 0.02
Concomitant procedure
  Percutaneous coronary intervention, n (%) 8 (5.3%) 45 (10.1%) 0.07
  Carotid stenting, n (%) 0 (0.0%) 1 (0.2%) 1.00
  Iliofemoral stenting, n (%) 5 (3.3%) 17 (3.8%) 1.00
Device features
  Valve size
   23 mm 42 (27.5%) 108 (24.3%) 0.45
   26 mm 72 (47.1%) 257 (57.8%) 0.02
   29 mm 39 (25.5%) 80 (18.0%) 0.05
  Prior balloon aortic valvuloplasty, n (%) 143 (93.5%) 410 (92.1%) 0.72
Device features
  Mean transprosthetic gradient, mm Hg
   For 23 mm valve size 11.65±5.98 9.96±4.77 0.08
   For 26 mm valve size 9.00±3.66 8.18±5.61 0.25
   For 29 mm valve size 8.49±3.42 7.42±4.59 0.23
  Aortic valve area, mm
   For 23 mm valve size 1.43±0.33 1.51±0.43 0.38
   For 26 mm valve size 1.73±0.37 1.89±0.58 0.09
   For 29 mm valve size 1.93±0.50 2.24±0.81 0.15
Aortic regurgitation post-TAVI n=150 n=439
  Grade 0, n (%) 86 (57.3%) 140 (31.9%) <0.01
  Grade 1, n (%) 62 (41.3%) 276 (62.9%) <0.01
  Grade 2, n (%) 2 (1.3%) 20 (4.6%) 0.08
  Grade 3, n (%) 0 (0.0%) 3 (0.7%) 0.57
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mostly depend on the THV type implanted. Although PPM 
rates of 20% to 30% with the self-expanding CoreValve13,31 
and almost 30% with the Lotus THV32 have been observed, 
the rate of higher degree atrioventricular block is lower for 
balloon-expandable THVs.33 Additional factors that predict 
PPM implantation after TAVI include preexisting right bun-
dle branch block34 or atrioventricular block, as well as THV 
implant depth35 and annulus oversizing.34 In our study, there 
were more new PPM implants in patients treated with the 
S3. This could be explained by the longer stent frame of the 
S3, which may protrude more into the left ventricular out-
flow tract, thereby compressing the interventicular septum. 
An inflammatory response to the external sealing skirt may 
be postulated, but is unlikely. Whether prudent higher THV 
implantations (80% aortal, 20% ventricular) may reduce the 
risk of conduction disturbances needs further investigation. 
Although the initial manufacturer recommendation was to 
place the middle marker of the deployment balloon in the 
annular plane, current clinical practice demonstrates that a 
high implant in experienced hands can be safely performed 
and may reduce atrioventricular conduction dusturbances.36 
Overall, there seems to be no prognostic impact of a new PPM 
after TAVI.34,37
Limitations
The grade of PAR in this study was defined by experienced on-
site echocardiographers and reported according to Valve Aca-
demic Research Consortium-2 criteria.18 The grading of PAR 
Figure 3. Paravalvular regurgitation after transcatheter aortic 
valve implantation with the Sapien 3 versus the Sapien XT trans-
catheter heart valve. Mild as well as more than mild paravalvular 
regurgitation was less frequently observed after implantation of 
the Sapien 3 compared with the Sapien XT transcatheter heart 
valve.
Table 3. 30-Days Clinical Outcomes
Sapien 3, N=153 Sapien XT, N=445 Odds Ratio OR (95% CI) P Value Adjusted OR (95% CI)
Adjusted 
P Value
Mortality, n(%) 5 (3.3) 20 (4.5) 0.72 (0.26–1.95) 0.56 0.63 (0.27–1.43) 0.27
  Cardiovascular mortality, n (%) 4 (2.6) 19 (4.3) 0.60 (0.20–1.80) 0.36 0.77 (0.32–1.81) 0.55
Cerebrovascular accident, n (%) 2 (1.3) 18 (4.0) 0.31 (0.07–1.37) 0.12  0.35 (0.10–1.15) 0.08
  Disabling stroke, n (%) 2 (1.3) 14 (3.1) 0.41 (0.09–1.81) 0.24 0.44 (0.10–1.99) 0.29
  Nondisabling stroke, n (%) 0 (0.0) 2 (0.4) 1.20 (0.03–15.51) 1.00
  TIA, n (%) 0 (0.0) 2 (0.4) 1.20 (0.03–15.51) 1.00
Myocardial infarction, n (%) 2 (1.3) 0 (0.0) 7.06 (0.55-∞) 0.13
  Periprocedural myocardial infarction, n (%) 2 (1.3) 0 (0.0) 7.06 (0.55-∞) 0.13
  Spontaneous myocardial infarction, n (%) 0 (0.0) 0 (0.0)
Acute kidney injury, n (%) 7 (4.6) 26 (5.8) 0.83 (0.35–1.98) 0.89 1.62 (0.54–4.86) 0.39
  Stage 1, n (%) 1 (0.7) 13 (2.9) 0.26 (0.03–2.08) 0.21 0.80 (0.18–3.58) 0.77
  Stage 2, n (%) 2 (1.3) 3 (0.7) 1.95 (0.32–11.79) 0.47
  Stage 3, n (%) 4 (2.6) 10 (2.2) 1.17 (0.36–3.78) 0.80 2.79 (0.56–13.94) 0.21
Bleeding, n (%) 14 (9.2) 66 (14.8) 0.50 (0.26–0.99) 0.05 0.76 (0.24–2.40) 0.64
  Life threatening bleeding, n (%) 6 (3.9) 24 (5.4) 0.64 (0.24–1.68) 0.36 1.16 (0.56–2.40) 0.68
  Major bleeding, n (%) 6 (3.9) 37 (8.3) 0.48 (0.19–1.18) 0.11 0.84 (0.21–3.45) 0.81
  Minor bleeding, n (%) 2 (1.3) 5 (1.1) 0.93 (0.13–6.59) 0.71
Vascular access site and access-related 
complications, n (%)
8 (5.2) 75 (16.9) 0.25 (0.11–0.57) <0.01 0.31 (0.17–0.59) <0.01
  Major vascular complications, n (%) 5 (3.3) 41 (9.2) 0.31 (0.11–0.85) 0.02 0.53 (0.27–1.04) 0.07
  Minor vascular complications, n (%) 2 (1.3) 34 (7.6) 0.16 (0.03–0.74) 0.02 0.09 (0.04–0.19) <0.01
Repeat unplanned intervention, n (%) 2 (1.3) 2 (0.4) 2.93 (0.41–21.01) 0.28
  Valve in valve treatment, n (%) 0 (0.0) 1 (0.2) 2.91 (0.00–113.43) 1.00
Permanent pacemaker implantation, n (%) 26 (17.0) 49 (11.0) 1.68 (0.99–2.84) 0.06 1.89 (1.16–3.08) 0.01
Depicted are number of first events with % of all patients at 30 days since procedure. Odds ratios (OR) from mixed effects logistic regressions accounting for random 
hospital identifier effects or exact logistic regressions in case of zero events (95% confidence interval [CI]). Adjusted odds ratios: see Methods for details. TIA indicates 
transient ischemic attack.
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after TAVI may be difficult and substantial inter- and intrao-
bserver variability may occur. The lack of a core laboratory 
may lead to heterogeneity in the assessment of this parameter. 
However, all sites contributed patients to both groups, which 
reduces center-specific assessments as a confounder, and out-
come assessments were corrected using random effects of the 
site.
As the S3 replaced the XT as default balloon-expand-
able THV, both groups were treated consecutively. A learn-
ing curve may be postulated explaining improved outcomes 
with the S3. However, all participating centers have started 
and gained extensive experience with TAVI before the SWISS 
TAVI registry was initiated. Furthermore, the introduction of a 
new device implicated a new learning curve for the S3, which 
would be in favor of the XT. Therefore, we do not anticipate 
that a learning curve explains the observations of this trial.
Assessments of clinical outcomes were not corrected for 
multiple testing, which may lead to the reporting of spuri-
ous significant effects. The reporting in this study followed 
the Valve Academic Research Consortium-2 criteria and were 
predefined. The reduction in vascular access site–related com-
plications does withstand correction for multiple testing by the 
Bonferroni method (0.05 divided by 9 main outcomes: 0.005). 
Otherwise, further assessments of clinical outcomes compar-
ing S3 versus XT is encouraged using a larger sample size 
of patients and longer follow-up. Because of the prospective 
design of this nationwide multicenter registry, data collection 
was restricted to variables defined at the launch of the registry. 
Therefore, no information on specific sizing algorithms and 
prosthesis implant depth are available.
Conclusions
The use of the new generation S3 balloon-expandable THV is 
associated with a significant reduction of more than mild PAR 
and vascular complications when compared with the XT. In 
contemporary clinical practice, TAVI using the newest genera-
tion balloon-expandable THV is associated with a low risk of 
stroke and overall favorable clinical outcomes.
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